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ABSTRACT The crystal structure of the human transcription factor DLX5 has been used for the screening of a 
library consisting of 106 compounds by the molecular docking technique. In vitro tests of the 14 top-rated ligands 
showed that compound Q12 displays the best ability to inhibit the proliferation of Dlx5 positive mouse lym-
phoma cells, which correlates with the down-regulation of c-myc expression. Compound Q12 has low toxicity 
on normal human ovarian epithelial cells and mouse lymphoma cells with absent expression of Dlx5, and can 
be used for further chemical optimization and for the development of novel, highly efficient cancer treatments. 
KEYWORDS DLX5; transcription factor; small molecules; cancer; molecular docking.
ABBREVIATIONS DLX5 – human transcription factor, encoded by gene DLX5 (Distall-less homeobox gene 5); 
Dlx5 – mouse transcription factor encoded by gene Dlx5; Kd – binding (affinity) constant; NSCLC - non-small 
cell lung cancer; siRNA – small interfering RNA, RT-PCR – reverse transcription polymerase chain reaction.
INTRODUCTION
A wide range of drugs have been used in modern clini-
cal practice in order to control cancer [1    –3]. However, 
even if all the available drugs were to be used, the pro-
portion of patients who respond to the therapy would 
remain rather small. For this reason is critically neces-
sary to design new efficient targeted methods for can-
cer treatment based on a deep comprehension of the 
mechanisms of tumor growth.
Recent discoveries reveal that the transcription fac-
tor DLX5 displays oncogenic activity. The overexpres-
sion of the DLX5 gene in mammalian cells stimulates 
cell proliferation [4] and can be observed in endome-
trial carcinoma, non-small cell lung cancer (NSCLC), 
and small cell lung cancer [5, 6]. The knockdown of the 
DLX5 expression using siRNA in mouse and human 
cancer cells results in the arrest of cell proliferation [4, 
7]. New data point to the fact that DLX5 has a direct 
effect on the expression of protooncogene c-myc [8]. All 
these facts allow us to regard DLX5 as a promising tar-
get for which specific ligands that have the properties 
of oncogenesis inhibitors can be found.
Attempts have frequently been made to use the so-
called “high throughput screening” to solve the prob-
lem of the search for the ligands of a certain protein [9–
13]. This screening is carried out on a cell culture or on 
an in vitro model, using an earlier prepared compound 
library. The logistics and cost of the studies required for 
the experimental validation of a significant number of 
molecules is prohibitively high in many cases. On ac-
count of these reasons, in the present study we used the 
algorithm earlier elaborated to search for inhibitors of 
new protein targets, based on the analysis of the crystal 
structure of a target protein [14]. The algorithm is based 
on the molecular docking of chemical compounds to the 
known 3D model of a target protein, which predicts the 
possible position of a compound in the protein–ligand 
binding site, the calculation of the molecular dynamics 
being used to refine the binding energies for the best 
suiting compounds. As shown in our study, as well as in 
previous  studies [14–19],  this multi-level approach  is 
not only efficient, but it also considerably reduces the 
amount  of experiments to be carried out. In this case, 
it enabled the discovery of several ligands of the tran-
scription factor DLX5 that have potential for cancer 
therapy.
EXPERIMENTAL
Ligand preparation and molecular docking
In order to optimize the time of computational screen-
ing, the ENAMINE library consisting of 106 compounds 
was clustered using the Jarvis–Patrick algorithm [20, 
21] with acceleration [22], which is contained in the 
QUANTUM software package. The so-called Tanimoto 
metric was calculated using the Daylight molecular 48 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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fingerprints, which were selected as the measure of 
molecular similarity [23]. The parameters of clusteri- of clusteri-  clusteri-
zation were selected in such a manner that each clus-
ter consisted, on average, of approximately 10  related 
structures; the total number of non-clustered mole-
cules being no higher than 20% of the initial amount of 
the library compounds. The compounds representing 
the centroids of clusters were then selected for further 
screening. In order to enhance the speed of molecular 
docking, from the entire centroid library were selected 
the molecules with the low molecular weight. All the 
selected compounds were extracted from the sdf files 
provided by ENAMINE and processed in the batch-
mode. The library had not been additionally enriched 
with molecules active towards oncotargets or by any 
other methods. The typization of protein and ligands, 
as well as in silico screening, was carried out using the 
corresponding tools from the QUANTUM software 
package.
The software predicts the binding (affinity) con-
stants (Kd) between small molecules and a target pro-
tein with an accuracy of approximately one order of 
magnitude, through the estimation of their intermo-
lecular interactions, by using accurate models of atomic 
forces in an aqueous environment [14, 24–26]. The hier-
archy of physical models of intermolecular interactions 
was used for calculations. In order to initially find the 
position of a ligand in the active site of a protein and 
estimate the binding energy of the protein–ligand com-
plex, docking of the ligand to the rigid protein structure 
was carried out; the results were then refined using the 
flexible protein model. The modified model of inter and 
intramolecular interactions AMBER/GAFF were used 
[27] in order to estimate the potential energy of inter-
action. The free energy was estimated using the linear 
interaction model [28]. An aqueous environment was 
simulated using the modified generalized Born model 
[25]. The algorithm was described earlier [14], where it 
was used to search for the inhibitors of protein–protein 
interactions.
Molecular docking of the molecules from the initial 
compound library was performed to the rigid structure 
of the DLX5 2DJN protein obtained from the Protein 
Data Bank (PDB) [29]. The region of the 3D structure 
that was selected for molecular docking was 2 x 2 x 2 nm 
in size. The ligands with the best predicted binding en-
ergies were recalculated to the models with a flexible 
protein [14, 15]. In order to verify that the selected mol- selected mol- mol-
ecules had not been described earlier, the following facts 
were checked: whether or not these compounds and/
or their analogues had been contained in the database 
or had been mentioned in the reviews devoted to the 
known inhibitors.
Cell cultures
In the present study we used the earlier characterized 
[30] line 42 of T-cell lymphoma from Akt2-transgenic 
mice (42-936, 42-577, and 42-588) and line 72 (wtl36). 
The cells were incubated in the Iscove’s MDM medium 
containing 10% of fetal bovine serum (FBS).The other 
cell lines were incubated in the RPMI medium with 10% 
of FBS. All cell cultures were kept at 370С at an atmos-
phere of 5% CO2. Potential inhibitors of DLX5 (Dlx5) 
were added to the medium containing 105 tumor cells 
at a concentration of 10 µM followed by incubation for 
96 h at 370С. The cell proliferation was assessed using 
the CellTiter 96 Aqueous One Solution Assay (Prome-
ga) in accordance with the manufacturer’s protocol. 
Each experiment was repeated at least three times.
RNA extraction and real-time RT-PCR
The RNA was extracted from the line 42 mouse T-cell 
lymphoma cells after incubation with compound Q12 
and DMSO for 96 h using the RNAqueous® Kit, in ac-
cordance with the manufacturer’s protocol. Real-time 
RT-PCR (repeated at least in triplicates) was carried 
out in a specialized service of the Fox Chase Cancer 
Center. The samples for estimation of the expression 
of the c-myc, Dlx5, and Tbp genes were synthesized at 
Applied Biosystems.
RESULTS AND DISCUSSION
Screening for the new ligand molecules specific to 
DLX5 has been carried out with The QUANTUM soft-
ware suite, based on the analysis of the protein crystal 
structure [14, 24–26]. This approach not only enables 
the identification of the molecules with potential to bind 
with a certain protein, but also allows us to minimize the 
quantity of false positive results, when the molecules 
with a high binding energy predicted in silico manifest-
ed no functional activity in the experiment. The search 
was made more complicated by the absence of prelimi-
nary data on the binding of the known compounds with 
DLX5 protein; therefore, blind studies were performed. 
The best molecules and all their structural analogues 
from the original ENAMINE library were sorted on the 
basis of their predicted binding energy. According to the 
results of molecular docking, 100 ligands were selected; 
14 of those with the best predicted binding energy of 
DLX5 protein were ordered and synthesized at ENAM-
INE company; then, they were tested on cell cultures. 
Figure 1 shows an example of molecular docking with an 
active DLX5 site of one of these ligands.
The cells of the earlier characterized line 42 of T-cell 
lymphoma from Akt2-transgenic mice [4, 30] were used 
as a model to verify the specific activity of the select-
ed ligands. These cells bear a clonal chromosome rear-
rangement –chromosome 6 inversion, which results in RESEARCH ARTICLES
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the translocation of the Dlx5 gene into the region under 
control of the T-cell enhancer and in the overexpression 
of Dlx5 protein. Lymphoma cells 42-936 were incubated 
with each of the 14 selected DLX5 ligands; the impact 
of the ligands on proliferation was assessed. As can be 
seen in Fig. 2A, the ligands demonstrate different effi- effi-
cacies of impact on the proliferation of lymphoma cells; 
compounds Q8, Q12, Q9, and Q13 manifested the best 
inhibitory activity. The possible nonspecific cyto-toxic 
action of the selected compounds was tested on normal 
human ovarian epithelial cells without DLX5 expres-
sion (Fig. 2B). When comparing with the control, it can 
be seen that most ligand molecules, with the exception 
of the compounds Q8 and Q13, manifest no significant 
cyto-toxicity. Since Q8 and Q13 manifested a cytotoxic 
effect, they were eliminated from further considera-
tion. Compounds Q12 and Q9 were selected for further 
studies as the most promising ones.
In order to eliminate the possibility of a nonspecific 
impact of compounds Q12 and Q9 on cells of the lym- compounds Q12 and Q9 on cells of the lym- Q12 and Q9 on cells of the lym-
phoid series, their action was tested on T-cell lympho-
ma cells of line 72 with absent expression of Dlx5 from 
Akt2-transgenic mice (Fig. 3). Cells of line 72 contain 
another type of chromosome rearrangement, a trans-
location between chromosomes 14 and 15 (t(14:15)), 
which results in an increased expression of protoonco-
gene c-myc [30]. Figure 4 shows the results of the effect 
of compound Q12 on the proliferation of an additional 
two  subtypes of lymphoma cells expressing Dlx5 (42-
577 and 42-588), as well as the proliferation of the hu-
man lymphoma cells Jurkat and Molt16 not expressing 
DLX5. A general conclusion can be made from the data 
presented in Figs. 3 and 4 that compounds Q9 and Q12 
have no effect on the proliferation of cells not express-
ing Dlx5; however, they are highly efficient in the sup-
pression of the proliferation of cells in which this factor 
is expressed.
It is known that the DLX5 transcription factor can 
directly control the expression of protooncogene c-myc 
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Fig. 2. Experimental estimation of the properties of 14 
compounds, for which high binding energy for the 3D 
structure of DLX5 was predicted: their efficacy was 
estimated by the impact on proliferation of Dlx5 posi-
tive mouse lymphoma cells 42-936 (A) and cytotoxicity 
measured by the impact on proliferation of normal human 
ovarian epithelial cells (B). K - is the level of proliferation in 
the control. The columns depicting the effect of the most 
promising compounds are labeled with asterisks (Q12(*) 
and Q9(**)).
Fig. 1. Molecular docking of one compound selected for 
further experiments: chemical structure and position of 
compound in the active site the transcription factor DLX5.50 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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[8, 30]. The impact of Q12 on the expression of c-myc in 
the lymphoma cells 42-936 expressing Dlx5 was stud-
ied by real-time RT-PCR. Figure 5 shows the levels of 
mRNA of c-myc with respect to the endogenous con-
trol, mRNA of TATA-binding protein (Tbp) or mRNA 
of Dlx5, as well as mRNA of Dlx5 with respect to 
mRNA of Tbp in the presence of 10 µM Q12 and with-
out any addition of it. It can be seen that the expression 
of c-myc decreases considerably under the action of 
Q12, while the expression of Dlx5 remains intact. These 
results agree with the conception of the inhibitory ef-
fect of ligand Q12 on the transcription activity of the 
Dlx5 factor. Although these data need to be tested on 
a larger number of cell lines, it is tempting to make a 
preliminary conclusion on the specificity of binding be-
tween the transcription factor DLX5 and ligand Q12 
based on the results of this study.
The approaches used in this study made it possible 
to experimentally identify the most active inhibitors 
of Dlx5 (DLX5) out of those that were tested. Further 
plans include optimizing the structure of the result-
ing compounds in terms of parameters such as the en-
hancement of efficacy, reduction of possible nonspe-
cific toxicity, and the enhancement of the metabolic 
stability. The next stage of this study assumes that 
the activity and toxicity of the optimized compounds 
will be assessed in vivo, and their Kd will be measured 
directly.
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Fig. 3. The selectivity of compounds Q12 and Q9 on 
mouse lymphoma cells. Left panel: the impact of com-
pounds on proliferation of Dlx5-positive mouse lymphoma 
cells 42-936. Right panel: the impact of compounds on 
proliferation of Dlx5-negative mouse lymphoma cells 
wtl36. Additional labeling is identical to that in Fig. 2.
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Fig. 4. Selectivity of compound Q12 on human lymphoma 
cells. On the left: proliferation of Dlx5-positive mouse lym-
phoma cells 42-577 and 42-588. On the right: prolifera-
tion of DLX5-negative human lymphoma cells Jurkat and 
Molt16. Additional labeling is identical to that in Fig. 2.
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Fig. 5. Real-time RT-PCR. The measurement of the expres-
sion of c-myc and Dlx5 in mouse lymphoma cells 42-936, 
after cultivation with 10 µM compound Q12 by the mRNA 
level. Tbp is the TATA-binding protein.
CONCLUSIONS
With the aim of verifying the fundamental possibility 
of using the DLX5 transcription factor as a target for 
anti-tumor agents and designing drugs that can sup-
press the development of certain types of human tu-
mors (T-lymphomas, lung and ovarian cancer), a search 
for specific ligands of the DLX5 factor was performed RESEARCH ARTICLES
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based on the analysis of its crystal structure. It was 
shown that more than 50% of compounds which were 
selected by docking technique are capable at micro-mo-
lar concentrations to inhibit the proliferation of mouse 
lymphoma cells expressing Dlx5. Moreover, most of the 
compounds active on Dlx5 positive lymphoma cells had 
no effect on other types of cells that do not express this 
transcription factor, which serves as evidence of the 
specificity of the selected molecules. Compounds Q12 
and Q9 were found to be the best in terms of the ratio 
between the parameter characterizing the efficacy and 
the absence of nonspecific cytotoxicity. The observed 
decrease in the expression of с-myc under the action of 
Q12 attests to the inhibitory effect of this ligand on the 
transcriptional activity of the Dlx5. The compounds dis-
covered are the first described low-molecular-weight 
ligands of DLX5 which can be used for subsequent 
chemical optimization and the development of highly 
efficient anti-tumor agents. 
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